New therapy found to prevent heart failure

Jun 23, 2009

A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) versus patients who received only an implanted cardiac defibrillator (ICD-only).

MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy) is a clinical trial that enrolled more than 1,800 patients in the United States, Canada and Europe and followed the patients for up to 4½ years. The results of the trial were released today by the University of Rochester Medical Center and Boston Scientific, the study's sponsor. The MADIT-CRT Executive Committee stopped the trial on June 22, 2009, when the trial achieved its primary end point - significant reduction in or death with CRT-D versus ICD-only. Cardiologist Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, led the MADIT-CRT trial.

A prior study (MADIT-II) by Moss and associates in 2002 showed the ICD was effective in reducing mortality. The current MADIT-CRT study sought to determine if CRT-D could reduce the risk of mortality and heart failure, which affects 5.7 million Americans, and the results are very positive.

Patients with have a risk of arrhythmias and heart failure. The new generation of cardiac resynchronization therapy defibrillators (CRT-Ds) was designed to stop dangerous, life-threatening and improve the heart's contraction, thereby enabling the device to improve survival and prevent heart failure.

CRT-D's are approved for use in patients with severe heart failure (New York Heart Association class III/IV), where they have been shown to reduce heart failure symptoms. The findings from the current study indicate that CRT-D therapy improves cardiac function and prevents the development of heart failure in patients who have not previously experienced heart failure.

"Now we can prevent sudden cardiac death and inhibit the development of , thus improving survival and outcome in patients with heart disease," Moss said. "There is a very large population of patients with heart disease who will benefit from this combined therapy."

Source: University of Rochester Medical Center (news : web)

Explore further: How proteins evolved the capacity for movement within cells

Related Stories

New heart failure device is tested

Oct 17, 2006

Physicians at 50 U.S. medical facilities are taking part in a multinational clinical trial of a device designed to help heart failure victims.

Recommended for you

How proteins evolved the capacity for movement within cells

4 hours ago

The process behind how the molecular components of living organisms start to move has been explained for the first time in new research published by Science and it is an intricate set of dance steps where the tempo is set ...

How do neural cells respond to ischemia?

5 hours ago

A group of researchers from the Lomonosov Moscow State University, in collaboration with their Irish colleagues from the University College Cork, has studied the early response of cells to ischemia, which ...

Shedding light on rods

May 05, 2015

By using "unusual" optic fibres in a novel fashion, an international team of researchers led by the International School for Advanced Studies (SISSA) in Trieste, scrutinized the response to light of rods, ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.